Tosoh Bioscience, Inc.

Ren'd 9125/09 K091332

OCT - 2 2009

# Section 5

# 510(K) Summary

Tosoh Bioscience, Inc.

# 510k Summary

# Tosoh AIA-PACK RBC FOLATE

# Date:

April 15, 2009

# Submitter:

Tosoh Bioscience, Inc. 3600 Gantz Road Grove City, OH 43123

# Contact Person:

Judith K. Ogden   
Director, New Business and Technical Development Tosoh Bioscience, Inc.   
6000 Shoreline Court, Suite 101,   
South San Francisco, CA 94080   
Phone: (650) 636-8112

# Device Name:

AIA-PACK RBC FOLATE

Classification Name:

Class II   
CGN   
21 CFR 862.1295 Folic Acid Test System

Predicate Device:

K010050, ADVIA Centaur and ACS: 180 Folate Immunoassay, Manufactured by Bayer Diagnostics Corp.

Tosoh Bioscience, Inc.

# 510(k) Summary

# AIA-PACK RBC FOLATE

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Device Description:

The Tosoh AIA-PACK RBC FOLATE is a competitive enzyme immunoassay which, after sample hemolysis and sample pretreatment, is performed entirely within the AIAPACk. First, sample hemolysis is performed to achieve complete hemolysis of erythrocytes and deconjugation to monoglutamate in the whole blood sample using sample hemolyzing reagents (containing ascorbic acid). After sample hemolysis, sample pretreatment is performed to release folate from endogenous binding proteins in the hemolysate sample using sample pretreatment reagents (containing sodium hydroxide and dithiothreitol).

Folate present in the pretreated test sample competes with enzyme-labeled folate for a limited number of binding sites on a fluorescein labeled bovine folate binding protein which then binds to anti-FITC (fluorescein isothiocyanate) antibody immobilized on magnetic beads. The beads are washed to remove the unbound enzyme-labeled folate and are then incubated with a fluorogenic substrate, 4-methylumbeliferyl phosphate (4MUP). The amount of enzyme labeled folate that binds to the beads is inversely proportional to the folate concentration in the test sample. A standard curve using a range of known standard concentrations is constructed and unknown folate concentrations are calculated using this curve.

The following products are required to use the Tosoh AIA-PACK RBC FOLATE.   
AIA-PACK RBC FOLATE Calibrator Set.   
AIA-PACK RBC FOLATE Sample Diluting Solution.   
AIA-PACK RBC FOLATE Pretreatment Set.   
AIA-PACK RBC FOLATE Hemolyzing Reagent Set.

# Device Intended Use:

AIA-PACK RBC Folate is designed for in vitro diagnostic use only for the quantitative measurement of red blood cell folate (RBC FOLATE) in whole blood (heparin or EDTA) samples on Tosoh AIA system analyzer. Measurement of RBC Folate is used in the diagnosis and treatment of anemia.

# Substantial Equivalence:

Comparison between Tosoh and Bayer -RBC Folate   

<table><tr><td rowspan=1 colspan=1>Specifications</td><td rowspan=1 colspan=1>Tosoh AIA-PACK RBCFOLATE</td><td rowspan=1 colspan=1>Bayer ADVIA CentaurÂ®FOL Lite ReagentK010050</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In Vitro Diagnostic Use for thequantitative measurement ofred blood cell folate (RBCFOLATE). Measurement ofRBC Folate is used in thediagnosis and treatment ofanemia.</td><td rowspan=1 colspan=1>In Vitro Diagnostic Usefor the quantitativedetermination of folate inserum or red blood cells.</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive enzymeimmunoassay usingfluorescence detection</td><td rowspan=1 colspan=1>Competitiveimmunoassay usingdirect chemiluminescenttechnology</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Whole blood EDTA or heparin</td><td rowspan=1 colspan=1>Whole blood EDTA orheparin</td></tr><tr><td rowspan=1 colspan=1>Assay Components</td><td rowspan=1 colspan=1>AIA-PACK RBC FOLATE testcups, pretreatment set,hemolyzing reagent set,calibrator set, sample dilutingsolution</td><td rowspan=1 colspan=1>ADVIA Centaur Litereagent pack, DTT/Releasing Agent, FOLAscorbic acid/Ascorbicacid diluent, FOLdiluent, FOL calibrator</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Lyophilized magnetic beadscoated with anti-FITC mousemonoclonal antibody andfluorescein labeled bovinefolate binding protein andpreservatives</td><td rowspan=1 colspan=1>Purified avidin bondedto paramagneticparticles in buffer withhuman serum albuminand preservatives</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Alkaline phosphatase</td><td rowspan=1 colspan=1>Acridinium ester</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>6-point calibration</td><td rowspan=1 colspan=1>2-point calibration</td></tr><tr><td rowspan=1 colspan=1>Assay Low</td><td rowspan=1 colspan=1>0.62 ng Folate/mL (based onLOQ)</td><td rowspan=1 colspan=1>0.35 ng/mL (MDC)</td></tr><tr><td rowspan=1 colspan=1>Assay High</td><td rowspan=1 colspan=1>24 ng Folate/mL</td><td rowspan=1 colspan=1>24 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Calibration Frequency</td><td rowspan=1 colspan=1>90 Days</td><td rowspan=1 colspan=1>7 Days</td></tr><tr><td rowspan=1 colspan=1>Time to preparehemolysate</td><td rowspan=1 colspan=1>30 minutes</td><td rowspan=1 colspan=1>90 minutes</td></tr><tr><td rowspan=1 colspan=1>Incubation</td><td rowspan=1 colspan=1>40 Minutes</td><td rowspan=1 colspan=1>5 Minutes + 2.5 Minutes</td></tr><tr><td rowspan=1 colspan=1>Specimen Vol (Hemolysate)</td><td rowspan=1 colspan=1>160 uL</td><td rowspan=1 colspan=1>150 uL</td></tr><tr><td rowspan=1 colspan=1>Specimen Volume (WholeBlood)</td><td rowspan=1 colspan=1>50 uL</td><td rowspan=1 colspan=1>50 uL</td></tr><tr><td rowspan=1 colspan=1>Reference Range</td><td rowspan=1 colspan=1>3.4 - 10.3 ng folate/mL148 - 531 ng RBC folate/mL</td><td rowspan=1 colspan=1>280-791 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Hemolyzing Reagent-1(5mL) Stability</td><td rowspan=1 colspan=1>1 day after reconstitution</td><td rowspan=1 colspan=1>30 days afterreconstitution</td></tr><tr><td rowspan=1 colspan=1>Hemolyzing Reagent -2 (65mL) Stability</td><td rowspan=1 colspan=1>30 days after reconstitution</td><td rowspan=1 colspan=1>Not applicable</td></tr><tr><td rowspan=1 colspan=1>Hemolysate Stability</td><td rowspan=1 colspan=1>5 Hours</td><td rowspan=1 colspan=1>3 Hours</td></tr></table>

Tosoh Bioscience, Inc.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Frozen - 60 days</td><td rowspan=1 colspan=1>Frozen - 90 days</td></tr><tr><td rowspan=1 colspan=1>Hemolysate MultiplicationFactor</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Calculation Of Final Results</td><td rowspan=1 colspan=1>Manual</td><td rowspan=1 colspan=1>Automatic</td></tr><tr><td rowspan=1 colspan=1>Corrected Value For RBCFolate In High SerumFolate Samples</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr></table>

# Recovery:

Recovery: Three whole blood (EDTA) samples were spiked with three different levels of RBC Folate and assayed before and after spiking.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>InitialValue(ngFolate/mL)</td><td rowspan=1 colspan=1>FolateAdded(ng/mL)</td><td rowspan=1 colspan=1>ExpectedValue(ngFolate/mL)</td><td rowspan=1 colspan=1>MeasuredValue (ngFolate/mL)</td><td rowspan=1 colspan=1>ExpectedValue(ng RBCfolate/mL)</td><td rowspan=1 colspan=1>MeasuredValue(ng RBCfolate/mL)</td><td rowspan=1 colspan=1>PercentRecovery(%)</td></tr><tr><td rowspan=1 colspan=1>SampleA1</td><td rowspan=1 colspan=1>4.94.94.9</td><td rowspan=1 colspan=1>5.110.120.3</td><td rowspan=1 colspan=1>10.015.025.2</td><td rowspan=1 colspan=1>10.215.224.6</td><td rowspan=1 colspan=1>487.0735.01230.9</td><td rowspan=1 colspan=1>500.1744.41205.0</td><td rowspan=1 colspan=1>102.7101.397.9</td></tr><tr><td rowspan=1 colspan=1>SampleB1</td><td rowspan=1 colspan=1>2.02.02.0</td><td rowspan=1 colspan=1>5.310.521.0</td><td rowspan=1 colspan=1>7.212.523.0</td><td rowspan=1 colspan=1>7.212.322.4</td><td rowspan=1 colspan=1>353.6610.51124.2</td><td rowspan=1 colspan=1>352.8601.71095.4</td><td rowspan=1 colspan=1>99.898.697.4</td></tr><tr><td rowspan=1 colspan=1>SampleC1</td><td rowspan=1 colspan=1>5.45.45.4</td><td rowspan=1 colspan=1>5.310.521.0</td><td rowspan=1 colspan=1>10.715.926.4</td><td rowspan=1 colspan=1>10.715.224.9</td><td rowspan=1 colspan=1>520.7777.61291.4</td><td rowspan=1 colspan=1>521.6743.01216.1</td><td rowspan=1 colspan=1>100.295.594.2</td></tr></table>

Dilution: Three whole blood (EDTA) samples containing high concentrations of folate were serially diluted with AIA-PACK RBC FOLATE SAMPLE DILUTING SOLUTION and assayed.   

<table><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">DilutionFactor</td><td colspan="1" rowspan="1">ExpectedValue (ngFolate/mL)</td><td colspan="1" rowspan="1">MeasuredValue(ngFolate/mL)</td><td colspan="1" rowspan="1">ExpectedValue(ng RBCfolate/mL)</td><td colspan="1" rowspan="1">MeasuredValue(ng RBCfolate/mL)</td><td colspan="1" rowspan="1">PercentRecovery(%)</td></tr><tr><td colspan="1" rowspan="1">Sample A2Hematocrit:45.0%</td><td colspan="1" rowspan="1">None7.5/105.0/102.5/101.0/10</td><td colspan="1" rowspan="1">32.424.316.28.13.2</td><td colspan="1" rowspan="1">32.425.417.38.63.2</td><td colspan="1" rowspan="1">1583.71187.7791.8395.9158.4</td><td colspan="1" rowspan="1">1583.71242.9844.2419.1158.4</td><td colspan="1" rowspan="1">100.0104.6106.6105.9100.0</td></tr><tr><td colspan="1" rowspan="1">Sample B2Hematocrit:45.0%</td><td colspan="1" rowspan="1">None7.5/105.0/102.5/101.0/10</td><td colspan="1" rowspan="1">22.516.911.25.62.2</td><td colspan="1" rowspan="1">22.517.211.66.42.5</td><td colspan="1" rowspan="1">1098.8824.1549.4274.7109.9</td><td colspan="1" rowspan="1">1098.8840.2566.4315.2124.3</td><td colspan="1" rowspan="1">100.0102.0103.1114.7113.1</td></tr><tr><td colspan="1" rowspan="1">Sample C2</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">7.7</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">444.5</td><td colspan="1" rowspan="1">444.5</td><td colspan="1" rowspan="1">100.0</td></tr><tr><td rowspan="2">Hematocrit:37.9%</td><td rowspan="2">7.5/10 5.0/10</td><td>5.7</td><td>7.1</td><td rowspan="2">333.4 222.3</td><td>348.0</td><td>104.4</td></tr><tr><td>2.1</td><td>4.9</td><td></td><td>107.2</td></tr><tr><td rowspan="4"></td><td>2.5/10</td><td>0.5</td><td>2.6</td><td>111.1</td><td>238.3 125.1</td><td>112.5</td></tr><tr><td></td><td>0.1</td><td></td><td></td><td></td><td></td></tr><tr><td>1.0/10</td><td></td><td>0.9</td><td>44.5</td><td>45.8</td><td>103.0</td></tr></table>

Linearity: The linearity testing for AIA-PACK RBC FOLATE was based on CLSI Protocol EP6-A. The linearity was measured on the AIA-1800, and was demonstrated to be linear from 0.5 to 40.0 ng /mL, within $\pm 1 0 \%$ difference in this interval. The claimed linearity was 0.62 to 24.0 ng /mL based on discussion with the U.S. FDA.

# Precision:

The precision protocol for AIA-PACK RBC FOLATE followed CLSI EP5-A2. Precision studies were conducted at one site over a period of 92 days. An AlA-1800 was used to collect the data. All data was collected on one calibration curve by one operator. The lot number of the reagent pack was G611660 and the lot number of the calibrator set was 6075 C1-C6.

2a) Within run precision was determined using three commercially available controls and one whole blood control (EDTA) in a total of 20 runs. Within each run, one set of duplicates per control was assayed. The mean of each duplicate was used to obtain the pooled standard deviation (SD), which was then used to calculate the coefficient of variation (CV).

<table><tr><td>Sample</td><td>Hematocrit (%)</td><td>Mean (ng Folate/mL)</td><td>SD (ng Folate/mL)</td><td>Mean (ng RBC folate/mL)</td><td>CV (%)</td></tr><tr><td>Control 1 Control 2 Control 3 Sample A3</td><td>45.0 45.0 45.0 45.0</td><td>1.90 6.92 23.33 6.14</td><td>0.112 0.232 0.509 0.133</td><td>92.8 338.2 1140.5 300.4</td><td>5.9 3.4 2.2 2.2</td></tr></table>

2b) Total precision was determined by the duplicate assay of three commercially available controls and one whole blood (EDTA) control in 20 separate runs. The means of each run were used to calculate the standard deviation (SD) and coefficient of variation (CV).

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Hematocrit(%)</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD(ngFolate/mL)</td><td rowspan=1 colspan=1>Mean(ng RBC folate/mL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Control 1Control 2Control 3Sample A3</td><td rowspan=1 colspan=1>45.045.045.045.0</td><td rowspan=1 colspan=1>1.906.9223.336.14</td><td rowspan=1 colspan=1>0.1550.3170.7610.256</td><td rowspan=1 colspan=1>92.8338.21140.5300.4</td><td rowspan=1 colspan=1>8.24.63.34.2</td></tr></table>

Tosoh Bioscience, Inc.

# Correlation:

The correlation between whole blood (EDTA) and whole blood (heparin) was performed using 50 patient samples.

<table><tr><td rowspan="2"></td><td colspan="2">After Correction for dilution factor</td><td colspan="2">After correction for dilution and hematocrit</td></tr><tr><td>Deming</td><td>Linear</td><td>Deming</td><td>Linear</td></tr><tr><td>Slope</td><td>regression 0.959</td><td>Regression 0.951 (0.914 to</td><td>Regression 0.955 (0.917 to</td><td>Regression</td></tr><tr><td rowspan="2"></td><td>(0.922 to 0.996)</td><td>0.988)</td><td>0.993)</td><td>0.946 (0.908 to</td></tr><tr><td></td><td>- 2.133 (-11.736</td><td>- 9.144 (-36.130</td><td>0.984)</td></tr><tr><td rowspan="2">y-Intercept</td><td>- 3.890 (-13.512</td><td></td><td></td><td>4.068 (-30.996</td></tr><tr><td>to 5.732)</td><td>to 7.469)</td><td>to 17.842)</td><td>to 22.860)</td></tr><tr><td>Correlation Coefficient</td><td>0.99</td><td></td><td>0.99</td><td></td></tr><tr><td>Number of Samples (n)</td><td>50</td><td></td><td>50</td><td></td></tr><tr><td>Measurement Range</td><td>34.90 to 523.37 ng folate/mL</td><td></td><td>151.59 to 1404.65 ngRBC folate/mL</td><td></td></tr></table>

The conclusion is that whole blood (heparin) specimens were found to be substantially equivalent in performance to whole blood (EDTA) specimens.

The correlation protocol for AIA-PACK RBC FOLATE followed CLSI Protocol EP9-A2. The correlation for AIA-PACK RBC FOLATE was determined based on guidance from CLSI Protocol EP9-A2. The correlation between AIA-PACK RBC FOLATE and an alternate method was carried out using 101patient specimens.

<table><tr><td colspan="3">After Correction for dilution factor</td><td colspan="2">After correction for dilution and hematocrit</td></tr><tr><td></td><td>Deming</td><td>Linear</td><td>Deming</td><td>Linear</td></tr><tr><td rowspan="2">Slope</td><td>regression</td><td>Regression</td><td>Regression</td><td>Regression</td></tr><tr><td>1.06 (0.950 to</td><td>0.91 (0.805 to</td><td>1.00 (0.897 to</td><td>0.86 (0.761 to</td></tr><tr><td rowspan="2">y-Intercept</td><td>1.168)</td><td>1.015)</td><td>1.107)</td><td>0.964)</td></tr><tr><td>-19.554 (-44.640</td><td>12.22 (-11.909</td><td>-26.60</td><td>58.40</td></tr><tr><td></td><td>to 5.532)</td><td>to 36.353)</td><td></td><td></td></tr><tr><td>Correlation Coefficient</td><td colspan="2">0.87</td><td colspan="2">0.86</td></tr><tr><td>Number of Samples (n) Measurement Range</td><td colspan="2">101 49.06 - 491.04 ng folate/mL</td><td colspan="2">101 185 - 1333 ng RBC folate/mL</td></tr></table>

Specificity: The following substances were tested for cross-reactivity. The crossreactivity $( \% )$ is the percent of the compound which will be identified as RBC Folate. If these compounds are present in the specimen at the same concentration as RBC Folate, the final result will be increased by the percentages shown.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Cross-reactivity (%)</td></tr><tr><td rowspan=1 colspan=1>Amethopterin</td><td rowspan=1 colspan=1>2,518 ng/mL</td><td rowspan=1 colspan=1>0.66</td></tr><tr><td rowspan=1 colspan=1>Leucovorin</td><td rowspan=1 colspan=1>5,231 ng/mL</td><td rowspan=1 colspan=1>0.34</td></tr></table>

Tosoh Bioscience, Inc.

# Limit of Detection (LoD) and Limit of Quantitation (LoQ):

The limit of detection (LOD) and limit of quantitation (LOQ) for AIA-PACK RBC FOLATE was determined based on guidance from CLSI Protocol EP17-A. The blank sample was measured in 60 replicates. Seven low level samples were measured in 10 replicates each. The limit of detection for AIA-PACK RBC FOLATE was estimated to be 0.43 ng folate/mL. The limit of blank was 0.19 ngfolate/mL. The limit of quantitation was 0.62 ng folate/mL at $20 \%$ CV.

# Standards:

<table><tr><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=1>FDARecognitionNumber</td><td rowspan=1 colspan=1>Revision</td><td rowspan=1 colspan=1>Title</td></tr><tr><td rowspan=1 colspan=1>C28-A2NCCLS</td><td rowspan=1 colspan=1>7-81</td><td rowspan=1 colspan=1>June 2000</td><td rowspan=1 colspan=1>How to Define and Determine Reference Intervalsin the Clinical Laboratory; Approved Guideline -Second Edition</td></tr><tr><td rowspan=1 colspan=1>EP5-A2NCCLS</td><td rowspan=1 colspan=1>7-110</td><td rowspan=1 colspan=1>8/20/04</td><td rowspan=1 colspan=1>Evaluation of Precision Performance ofQuantitative Measurement Methods; ApprovedGuideline-Second Edition</td></tr><tr><td rowspan=1 colspan=1>EP6-ANCCLS</td><td rowspan=1 colspan=1>7-193</td><td rowspan=1 colspan=1>4/1/03</td><td rowspan=1 colspan=1>Evaluation of the Linearity of QuantitativeMeasurement Procedures; A Statistical Approach;Approved Guideline</td></tr><tr><td rowspan=1 colspan=1>EP9-A2NCCLS</td><td rowspan=1 colspan=1>7-92</td><td rowspan=1 colspan=1>9/20/02</td><td rowspan=1 colspan=1>Method Comparison and Bias Estimation UsingPatient Samples; Approved Guideline - SecondEdition</td></tr><tr><td rowspan=1 colspan=1>EP17-ANCCLS</td><td rowspan=1 colspan=1>7-194</td><td rowspan=1 colspan=1>10/20/04</td><td rowspan=1 colspan=1>Protocols for Determination of Limits of Detectionand Limits of Quantitation; Approved Guideline</td></tr></table>

# Conclusion:

The Tosoh Bioscience, Inc. AIA-PACK RBC FOLATE ASSAY is substantially equivalent to the Bayer K010050, ADVIA Centaur and ACS: 180 Folate Immunoassay for the quantitative measurement of red blood cell folate (RBC FOLATE) in whole blood (heparin or EDTA) samples on Tosoh AIA system analyzer.

Tosoh BioScience, Inc.   
c/o Ms. Judith K. Ogden   
Director, New Business & Technical Development 6000 Shoreline Court, Suite 101   
South San Francisco, CA 94080

Re: k091332 Trade Name: Tosoh AIA-Pack RBC Folate Regulation Number: 21 CFR $\ S 8 6 2 . 1 2 9 5$ Regulation Name: Folic Acid Test System. Regulatory Class: Class II Product Codes: CGN Dated: September 28, 2009 Received: September 29, 2009

OCT - 2 2009

Dear Ms. Ogden:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation.(21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/38791a1a8574ecb39671dbdb435dfacf8f1ec0591dc614083eadc96cd1826bfc.jpg)

Courtny C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indication for Use

510(k) Number (if known):

k091332

Device Name:

Tosoh AIA-PACK RBC FOLATE

Indication For Use:

Tosoh AIA-PACK RBC FOLATE is designed for in vitro diagnostic use only for the quantitative measurement of red blood cell folate (RBC FOLATE) in whole blood (Heparin or EDTA) samples on TOSOH AIA system analyzer. Measurement of RBC Folate is used in the diagnosis and treatment of anemia.

Prescription Use (21 CFR Part 801 Subpart D)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/2a9c60a7b368bc677ba601df64cb5b48d97821e815dbf0ca3da92b9b72c12013.jpg)

Division Sigh-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety